Drug intelligence / Profile preview

PTT-018

Development stage: Preclinical
Lead developer: Pyrotech Therapeutics
Modality: Small Molecules

Overview

PTT-018 is an early-discovery stage immuno-oncology drug candidate being developed by Pyrotech Therapeutics for the treatment of solid tumors. Pyrotech Therapeutics focuses on the development of small molecule modulators of the innate immune system, particularly targeting pathways involved in pyroptosis (programmed inflammatory cell death) to stimulate anti-tumor immunity. While PTT-018 is part of this specialized pipeline, its specific molecular target and chemical structure have not been publicly disclosed as of early 2024.

Beyond the preview

Go deeper on PTT-018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTT-018.

Explore the full profile